Cognitive Research Corporation Enhances Its Medical Leadership Team
Cognitive Research Corporation (CRC) has made a notable advancement by appointing four esteemed professionals to bolster its medical leadership team: Dr. Albena Patroneva, Dr. Mark Versavel, Dr. Sandeep Vaishnavi, and Dr. Djouher Hough. These skilled experts bring a wealth of knowledge in critical fields such as neurology, psychiatry, analgesia, and psychedelic research. Their expertise is expected to strengthen CRC's ability to provide cutting-edge scientific guidance and innovative solutions in clinical research.
Introduction of New Medical Directors
Dr. Mark Versavel, M.D., Ph.D., MBA, comes to CRC with over thirty years of rich experience in clinical development focused on neurology, clinical pharmacology, and pain management. His background includes significant roles at top pharmaceutical companies including Pfizer, Sunovion, and Eliem Therapeutics, showcasing his skill in bringing innovative therapies to market. Importantly, he played a key role in obtaining FDA approvals for crucial therapies such as Aptiom for epilepsy and Lyrica for fibromyalgia and neuropathic pain.
His Impact in Drug Development
Dr. Versavel’s influence reaches into translational medicine, where he has successfully set up vital test units for clinical pharmacology. His work has involved groundbreaking research on various medications for Alzheimer's disease and innovative solutions for pain management. His commitment to enhancing patient outcomes drives him to seek therapies that go beyond traditional methods.
Dr. Albena Patroneva's Valuable Experience
Dr. Albena Patroneva, M.D., MBA, contributes 25 years of thorough experience in both neurology and psychiatry clinical development. Her tenure with leading organizations like AstraZeneca and Teva Pharmaceuticals reflects her significant role in securing IND clearances and aiding the launch of several FDA-approved therapies, including PRISTIQ and TRINTELLIX for major depressive disorder. Dr. Patroneva’s proficiency in protocol design highlights her tremendous value to the CRC team, especially as they strive to excel in CNS research.
Dr. Sandeep Vaishnavi’s Advances in Neuropsychiatry
With over 20 years of dedicated research in neuropsychiatry, Dr. Sandeep Vaishnavi, M.D., Ph.D., FANPA, specializes in conditions such as ADHD, major depressive disorder, PTSD, and Alzheimer's disease. His role as principal investigator in clinical trials has led to important FDA approvals, including Rexulti for Alzheimer's-related agitation and Rejoyn as supplementary treatment for MDD. His established track record demonstrates a commitment to innovating treatment protocols and enhancing patient lives.
The Innovative Contributions of Dr. Djouher Hough
Dr. Djouher Hough, Psy.D., enhances the team with more than 15 years of extensive experience in areas including schizophrenia and substance use disorders. Her specialization in psychedelic research has placed her at the forefront of pioneering clinical trials that have directly influenced the FDA approvals of key medications such as Latuda and Austedo. Dr. Hough’s participation in Human Abuse Liability trials illustrates her dedication to ensuring safe and effective treatments for patients.
CRC's Vision for the Future
Cognitive Research Corporation is excited to embrace this remarkable group of medical directors, as expressed by Tom Zoda, Ph.D., CEO of CRC. He emphasized that the combined experience of Dr. Versavel, Dr. Patroneva, Dr. Vaishnavi, and Dr. Hough will significantly enhance CRC's medical and scientific capabilities, enabling the organization to deliver exceptional, tailored solutions for its clients. The dedication of this team is anticipated to bring substantial improvements to CRC's offerings, further solidifying its standing in the clinical research field.
About Cognitive Research Corporation (CRC)
Cognitive Research Corporation is a prominent full-service clinical research organization focusing on CNS disorders. The organization is dedicated to providing top-quality clinical trial services aimed at developing transformative treatments. Emphasizing innovation, collaboration, and scientific rigor, CRC partners with sponsors and CNS experts to navigate new drugs through rigorous testing processes, optimizing support for FDA submissions and enhancing patient outcomes.
Frequently Asked Questions
What areas do the new directors at CRC specialize in?
The newly appointed directors have expertise in neurology, psychiatry, analgesia, and psychedelic research.
How will CRC utilize the new directors to enhance patient outcomes?
By leveraging the extensive experience of these directors, CRC aims to boost its clinical development capabilities and introduce innovative treatment solutions.
What is the primary focus of Cognitive Research Corporation?
CRC is centered on clinical research involving CNS disorders, particularly in neurology and psychiatry.
What notable drugs have been developed by members of the new team?
The new directors have been integral in the development of significant drugs such as Lyrica and Aptiom from Merck, and PRISTIQ from AstraZeneca.
Who is in charge of Cognitive Research Corporation?
The CEO of CRC is Tom Zoda, Ph.D., who supports the new medical leadership team.
